Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Arie S. Belldegrun is a world-renowned urologic oncologist whose research has fundamentally shaped the modern management of kidney cancer. His key contributions center on renal cell carcinoma, particularly the evolution of nephron-sparing surgery and the development of evidence-based clinical guidelines. Dr. Belldegrun’s most impactful work is the landmark "Guideline for Management of the Clinical T1 Renal Mass" (2009), which has garnered over 1,800 citations, serving as the definitive framework for treating small renal tumors. This guideline, alongside his comprehensive review "Partial Nephrectomy: A Contemporary Review" (2008), championed partial nephrectomy as the standard of care, demonstrating its oncologic efficacy and superior renal function preservation over radical surgery. He has also advanced the understanding of upper tract urothelial carcinoma, notably through research on the prognostic role of surgical approach and lymph node dissection (2017). Beyond his research, Dr. Belldegrun is a pioneering surgeon who helped popularize laparoscopic and robotic-assisted partial nephrectomy, translating his findings into improved patient outcomes. His work has not only set the standard for clinical practice but has also profoundly influenced the training of a generation of urologic surgeons.